nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP3A4—bone cancer	0.473	1	CbGaD
Cyclophosphamide—CYP2B6—Cisplatin—bone cancer	0.0354	0.255	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—bone cancer	0.0237	0.171	CbGbCtD
Cyclophosphamide—CYP2C9—Cisplatin—bone cancer	0.0187	0.135	CbGbCtD
Cyclophosphamide—ABCB1—Cisplatin—bone cancer	0.0181	0.131	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—bone cancer	0.0122	0.0877	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—bone cancer	0.0118	0.085	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—bone cancer	0.0114	0.0826	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—bone cancer	0.00728	0.0525	CbGbCtD
Cyclophosphamide—Ifosfamide—CYP3A4—bone cancer	0.00277	1	CrCbGaD
Cyclophosphamide—CYP2C18—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00274	0.0434	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00182	0.0289	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00167	0.0265	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00135	0.0213	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Xenobiotics—CYP3A4—bone cancer	0.00132	0.0209	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00132	0.0209	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metapathway biotransformation—CYP4V2—bone cancer	0.00118	0.0187	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00114	0.0181	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00113	0.0179	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00109	0.0173	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00102	0.0161	CbGpPWpGaD
Cyclophosphamide—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000998	0.0158	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000963	0.0153	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00094	0.0149	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000936	0.0148	CbGpPWpGaD
Cyclophosphamide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000934	0.0148	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000933	0.0148	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000928	0.0147	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000887	0.0141	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000879	0.0139	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000845	0.0134	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.000806	0.0128	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000784	0.0124	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000775	0.0123	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000728	0.0115	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Tryptophan metabolism—CYP3A4—bone cancer	0.000679	0.0108	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000662	0.0105	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.00065	0.0103	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.000637	0.0101	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000635	0.0101	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000612	0.0097	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000611	0.00968	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.00058	0.00918	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000576	0.00912	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000567	0.00898	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000553	0.00876	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.00055	0.00872	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000549	0.0087	CbGpPWpGaD
Cyclophosphamide—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000546	0.00865	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000542	0.00858	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00054	0.00856	CbGpPWpGaD
Cyclophosphamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000537	0.00851	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000529	0.00839	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000501	0.00795	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000491	0.00778	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000491	0.00778	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000472	0.00748	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000452	0.00716	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000448	0.0071	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000446	0.00707	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000445	0.00705	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000438	0.00694	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000436	0.00691	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000434	0.00688	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000431	0.00682	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.000427	0.00676	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000425	0.00674	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000403	0.00638	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000399	0.00633	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000385	0.0061	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000365	0.00578	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00036	0.00571	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000337	0.00534	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000334	0.0053	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000331	0.00524	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00033	0.00523	CbGpPWpGaD
Cyclophosphamide—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000329	0.00522	CbGpPWpGaD
Cyclophosphamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000314	0.00497	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Tryptophan metabolism—MDM2—bone cancer	0.000312	0.00494	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000307	0.00487	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000296	0.00469	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000293	0.00464	CbGpPWpGaD
Cyclophosphamide—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	0.000281	0.00445	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000271	0.0043	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00027	0.00428	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000266	0.00422	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000264	0.00418	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000263	0.00417	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00026	0.00413	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Biological oxidations—CYP3A4—bone cancer	0.000236	0.00375	CbGpPWpGaD
Cyclophosphamide—Leukopenia—Cisplatin—bone cancer	0.000234	0.000727	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Epirubicin—bone cancer	0.000234	0.000724	CcSEcCtD
Cyclophosphamide—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	0.000233	0.00369	CbGpPWpGaD
Cyclophosphamide—Hepatic failure—Doxorubicin—bone cancer	0.00023	0.000713	CcSEcCtD
Cyclophosphamide—Cardiac failure—Epirubicin—bone cancer	0.000229	0.000709	CcSEcCtD
Cyclophosphamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000228	0.00362	CbGpPWpGaD
Cyclophosphamide—Cardiac failure congestive—Doxorubicin—bone cancer	0.000228	0.000706	CcSEcCtD
Cyclophosphamide—Convulsion—Cisplatin—bone cancer	0.000227	0.000703	CcSEcCtD
Cyclophosphamide—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000225	0.00357	CbGpPWpGaD
Cyclophosphamide—Hyponatraemia—Epirubicin—bone cancer	0.000224	0.000695	CcSEcCtD
Cyclophosphamide—Renal failure acute—Doxorubicin—bone cancer	0.000224	0.000694	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000223	0.000692	CcSEcCtD
Cyclophosphamide—Myalgia—Cisplatin—bone cancer	0.000223	0.000691	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—bone cancer	0.000221	0.000685	CcSEcCtD
Cyclophosphamide—Discomfort—Cisplatin—bone cancer	0.00022	0.000683	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—bone cancer	0.000219	0.000679	CcSEcCtD
Cyclophosphamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000219	0.00347	CbGpPWpGaD
Cyclophosphamide—Renal impairment—Doxorubicin—bone cancer	0.000217	0.000673	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—bone cancer	0.000216	0.00067	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000215	0.000666	CcSEcCtD
Cyclophosphamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000214	0.00339	CbGpPWpGaD
Cyclophosphamide—Anaphylactic shock—Cisplatin—bone cancer	0.000214	0.000663	CcSEcCtD
Cyclophosphamide—Oedema—Cisplatin—bone cancer	0.000214	0.000663	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Epirubicin—bone cancer	0.000212	0.000658	CcSEcCtD
Cyclophosphamide—Infection—Cisplatin—bone cancer	0.000212	0.000658	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—bone cancer	0.000212	0.000656	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Cisplatin—bone cancer	0.000209	0.000649	CcSEcCtD
Cyclophosphamide—Tachycardia—Cisplatin—bone cancer	0.000208	0.000647	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—bone cancer	0.000207	0.000643	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000207	0.000641	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Cisplatin—bone cancer	0.000207	0.000641	CcSEcCtD
Cyclophosphamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000204	0.00323	CbGpPWpGaD
Cyclophosphamide—Anorexia—Cisplatin—bone cancer	0.000204	0.000632	CcSEcCtD
Cyclophosphamide—CYP2C18—Biological oxidations—GSTP1—bone cancer	0.000202	0.0032	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000201	0.00319	CbGpPWpGaD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000201	0.000623	CcSEcCtD
Cyclophosphamide—Hypotension—Cisplatin—bone cancer	0.0002	0.000619	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—bone cancer	0.0002	0.000619	CcSEcCtD
Cyclophosphamide—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	0.000199	0.00316	CbGpPWpGaD
Cyclophosphamide—Abdominal discomfort—Methotrexate—bone cancer	0.000198	0.000613	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—bone cancer	0.000196	0.000609	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—bone cancer	0.000196	0.000607	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000195	0.000604	CcSEcCtD
Cyclophosphamide—Paraesthesia—Cisplatin—bone cancer	0.000192	0.000595	CcSEcCtD
Cyclophosphamide—Dyspnoea—Cisplatin—bone cancer	0.00019	0.000591	CcSEcCtD
Cyclophosphamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000188	0.00297	CbGpPWpGaD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000186	0.000577	CcSEcCtD
Cyclophosphamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000186	0.00295	CbGpPWpGaD
Cyclophosphamide—Decreased appetite—Cisplatin—bone cancer	0.000186	0.000576	CcSEcCtD
Cyclophosphamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000185	0.00294	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000185	0.00293	CbGpPWpGaD
Cyclophosphamide—Pneumonia—Methotrexate—bone cancer	0.000185	0.000573	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—bone cancer	0.000185	0.000573	CcSEcCtD
Cyclophosphamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000184	0.00291	CbGpPWpGaD
Cyclophosphamide—Pancytopenia—Epirubicin—bone cancer	0.000183	0.000568	CcSEcCtD
Cyclophosphamide—Pain—Cisplatin—bone cancer	0.000183	0.000567	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000182	0.000565	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—bone cancer	0.000181	0.00056	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—bone cancer	0.000179	0.000556	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—bone cancer	0.000179	0.000554	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—bone cancer	0.000176	0.000547	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Cisplatin—bone cancer	0.000176	0.000546	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—bone cancer	0.000176	0.000545	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—bone cancer	0.000175	0.000544	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—bone cancer	0.000174	0.00054	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—bone cancer	0.000173	0.000537	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—bone cancer	0.000172	0.000532	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000171	0.000529	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—bone cancer	0.00017	0.000526	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—bone cancer	0.000169	0.000524	CcSEcCtD
Cyclophosphamide—Body temperature increased—Cisplatin—bone cancer	0.000169	0.000524	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—bone cancer	0.000169	0.000523	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—bone cancer	0.000168	0.00052	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—bone cancer	0.000168	0.00052	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—bone cancer	0.000167	0.000519	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—bone cancer	0.000166	0.000514	CcSEcCtD
Cyclophosphamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000165	0.00262	CbGpPWpGaD
Cyclophosphamide—Haemorrhage—Methotrexate—bone cancer	0.000165	0.000512	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—bone cancer	0.000165	0.000512	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—bone cancer	0.000165	0.000511	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—bone cancer	0.000164	0.000509	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—bone cancer	0.000162	0.000504	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—bone cancer	0.000161	0.000499	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—bone cancer	0.000161	0.000498	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—bone cancer	0.00016	0.000496	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—bone cancer	0.000159	0.000493	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000158	0.000489	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Cisplatin—bone cancer	0.000157	0.000488	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—bone cancer	0.000157	0.000488	CcSEcCtD
Cyclophosphamide—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000157	0.00249	CbGpPWpGaD
Cyclophosphamide—Renal failure—Doxorubicin—bone cancer	0.000156	0.000485	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—bone cancer	0.000156	0.000484	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000156	0.000484	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—bone cancer	0.000155	0.000481	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—bone cancer	0.000155	0.000481	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—bone cancer	0.000155	0.000481	CcSEcCtD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000155	0.00246	CbGpPWpGaD
Cyclophosphamide—Rhinitis—Epirubicin—bone cancer	0.000155	0.00048	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—bone cancer	0.000155	0.00048	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—bone cancer	0.000154	0.000479	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—bone cancer	0.000154	0.000479	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—bone cancer	0.000154	0.000477	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—bone cancer	0.000154	0.000477	CcSEcCtD
Cyclophosphamide—Asthenia—Cisplatin—bone cancer	0.000153	0.000475	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—bone cancer	0.000153	0.000473	CcSEcCtD
Cyclophosphamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000152	0.00241	CbGpPWpGaD
Cyclophosphamide—Haematuria—Doxorubicin—bone cancer	0.000152	0.000471	CcSEcCtD
Cyclophosphamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000151	0.00239	CbGpPWpGaD
Cyclophosphamide—Visual impairment—Epirubicin—bone cancer	0.000149	0.000462	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—bone cancer	0.000149	0.000461	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—bone cancer	0.000148	0.000459	CcSEcCtD
Cyclophosphamide—Diarrhoea—Cisplatin—bone cancer	0.000146	0.000453	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—bone cancer	0.000146	0.000453	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—bone cancer	0.000146	0.000452	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—bone cancer	0.000145	0.000451	CcSEcCtD
Cyclophosphamide—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000144	0.00228	CbGpPWpGaD
Cyclophosphamide—Tinnitus—Epirubicin—bone cancer	0.000144	0.000447	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—bone cancer	0.000144	0.000445	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—bone cancer	0.000144	0.000445	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—bone cancer	0.000143	0.000444	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—bone cancer	0.000143	0.000444	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—bone cancer	0.000143	0.000443	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—bone cancer	0.000143	0.000443	CcSEcCtD
Cyclophosphamide—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000142	0.00226	CbGpPWpGaD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—bone cancer	0.000142	0.000441	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—NDUFA12—bone cancer	0.000142	0.00225	CbGpPWpGaD
Cyclophosphamide—Dysgeusia—Methotrexate—bone cancer	0.000141	0.000436	CcSEcCtD
Cyclophosphamide—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.00014	0.00223	CbGpPWpGaD
Cyclophosphamide—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.00014	0.00223	CbGpPWpGaD
Cyclophosphamide—Chills—Epirubicin—bone cancer	0.000139	0.00043	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—bone cancer	0.000138	0.000428	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—bone cancer	0.000138	0.000427	CcSEcCtD
Cyclophosphamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000137	0.00216	CbGpPWpGaD
Cyclophosphamide—Alopecia—Epirubicin—bone cancer	0.000136	0.000423	CcSEcCtD
Cyclophosphamide—Vomiting—Cisplatin—bone cancer	0.000136	0.000421	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—bone cancer	0.000135	0.00042	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—bone cancer	0.000135	0.000419	CcSEcCtD
Cyclophosphamide—Rash—Cisplatin—bone cancer	0.000135	0.000418	CcSEcCtD
Cyclophosphamide—Dermatitis—Cisplatin—bone cancer	0.000135	0.000417	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—bone cancer	0.000134	0.000417	CcSEcCtD
Cyclophosphamide—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000134	0.00213	CbGpPWpGaD
Cyclophosphamide—Ill-defined disorder—Methotrexate—bone cancer	0.000133	0.000413	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—bone cancer	0.000133	0.000413	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—bone cancer	0.000133	0.000412	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—bone cancer	0.000133	0.000411	CcSEcCtD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000133	0.0021	CbGpPWpGaD
Cyclophosphamide—Dysgeusia—Epirubicin—bone cancer	0.000132	0.000408	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—bone cancer	0.00013	0.000402	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—bone cancer	0.000129	0.000401	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—bone cancer	0.000129	0.000399	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—bone cancer	0.000128	0.000398	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—bone cancer	0.000128	0.000396	CcSEcCtD
Cyclophosphamide—Nausea—Cisplatin—bone cancer	0.000127	0.000394	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—bone cancer	0.000127	0.000393	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—bone cancer	0.000126	0.000392	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—bone cancer	0.000125	0.000389	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—bone cancer	0.000125	0.000387	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—bone cancer	0.000124	0.000386	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—bone cancer	0.000124	0.000386	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—bone cancer	0.000124	0.000385	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—bone cancer	0.000124	0.000383	CcSEcCtD
Cyclophosphamide—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.000123	0.00195	CbGpPWpGaD
Cyclophosphamide—Chest pain—Methotrexate—bone cancer	0.000122	0.000379	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—bone cancer	0.000122	0.000379	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—bone cancer	0.000122	0.000379	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—bone cancer	0.000122	0.000378	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—bone cancer	0.000121	0.000376	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—bone cancer	0.000121	0.000375	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—bone cancer	0.00012	0.000373	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—bone cancer	0.00012	0.000371	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—bone cancer	0.000119	0.000368	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—bone cancer	0.000118	0.000367	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—NT5C3A—bone cancer	0.000117	0.00186	CbGpPWpGaD
Cyclophosphamide—Cough—Epirubicin—bone cancer	0.000117	0.000364	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—bone cancer	0.000117	0.000364	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—bone cancer	0.000117	0.000364	CcSEcCtD
Cyclophosphamide—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000117	0.00186	CbGpPWpGaD
Cyclophosphamide—Convulsion—Epirubicin—bone cancer	0.000116	0.000361	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—bone cancer	0.000116	0.000361	CcSEcCtD
Cyclophosphamide—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000116	0.00184	CbGpPWpGaD
Cyclophosphamide—Hypertension—Epirubicin—bone cancer	0.000116	0.00036	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—bone cancer	0.000115	0.000358	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—bone cancer	0.000115	0.000357	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—bone cancer	0.000115	0.000356	CcSEcCtD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000115	0.00182	CbGpPWpGaD
Cyclophosphamide—Arthralgia—Epirubicin—bone cancer	0.000114	0.000355	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—bone cancer	0.000114	0.000355	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—bone cancer	0.000114	0.000355	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—bone cancer	0.000114	0.000354	CcSEcCtD
Cyclophosphamide—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000114	0.0018	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Methotrexate—bone cancer	0.000113	0.000351	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—bone cancer	0.000113	0.000351	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—bone cancer	0.000112	0.000348	CcSEcCtD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000112	0.00178	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000112	0.00177	CbGpPWpGaD
Cyclophosphamide—Anorexia—Methotrexate—bone cancer	0.000112	0.000347	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—bone cancer	0.000111	0.000345	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—bone cancer	0.000111	0.000343	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—bone cancer	0.00011	0.000341	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—bone cancer	0.00011	0.00034	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—bone cancer	0.00011	0.00034	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—bone cancer	0.00011	0.00034	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—bone cancer	0.000109	0.000338	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—bone cancer	0.000109	0.000337	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—bone cancer	0.000108	0.000335	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—bone cancer	0.000108	0.000334	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—bone cancer	0.000107	0.000333	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—bone cancer	0.000107	0.000333	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—bone cancer	0.000107	0.000332	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000107	0.000331	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—bone cancer	0.000106	0.000329	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—bone cancer	0.000106	0.000328	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—bone cancer	0.000106	0.000328	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—bone cancer	0.000106	0.000328	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—bone cancer	0.000105	0.000326	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—bone cancer	0.000105	0.000324	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—bone cancer	0.000105	0.000324	CcSEcCtD
Cyclophosphamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000105	0.00166	CbGpPWpGaD
Cyclophosphamide—Dyspnoea—Methotrexate—bone cancer	0.000105	0.000324	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—bone cancer	0.000103	0.000318	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—bone cancer	0.000102	0.000317	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—bone cancer	0.000102	0.000316	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—bone cancer	0.000102	0.000315	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—bone cancer	0.000102	0.000315	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—bone cancer	0.000101	0.000313	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—bone cancer	0.000101	0.000313	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—bone cancer	0.0001	0.000311	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.0001	0.00031	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—bone cancer	9.99e-05	0.00031	CcSEcCtD
Cyclophosphamide—CYP2B6—Biological oxidations—GSTP1—bone cancer	9.94e-05	0.00158	CbGpPWpGaD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—bone cancer	9.94e-05	0.000308	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—bone cancer	9.91e-05	0.000307	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—bone cancer	9.85e-05	0.000306	CcSEcCtD
Cyclophosphamide—CYP2C8—Biological oxidations—CYP3A4—bone cancer	9.84e-05	0.00156	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—bone cancer	9.81e-05	0.000304	CcSEcCtD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	9.8e-05	0.00155	CbGpPWpGaD
Cyclophosphamide—Dyspnoea—Epirubicin—bone cancer	9.78e-05	0.000303	CcSEcCtD
Cyclophosphamide—CYP3A5—Biological oxidations—GSTP1—bone cancer	9.72e-05	0.00154	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	9.7e-05	0.00154	CbGpPWpGaD
Cyclophosphamide—Anorexia—Doxorubicin—bone cancer	9.68e-05	0.0003	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—bone cancer	9.66e-05	0.0003	CcSEcCtD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	9.58e-05	0.00152	CbGpPWpGaD
Cyclophosphamide—Decreased appetite—Epirubicin—bone cancer	9.54e-05	0.000296	CcSEcCtD
Cyclophosphamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	9.53e-05	0.00151	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.51e-05	0.00151	CbGpPWpGaD
Cyclophosphamide—Hypotension—Doxorubicin—bone cancer	9.49e-05	0.000294	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—bone cancer	9.46e-05	0.000293	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—NDUFA12—bone cancer	9.42e-05	0.00149	CbGpPWpGaD
Cyclophosphamide—Pain—Epirubicin—bone cancer	9.38e-05	0.000291	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—bone cancer	9.38e-05	0.000291	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—bone cancer	9.31e-05	0.000289	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—bone cancer	9.27e-05	0.000287	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.25e-05	0.000287	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—bone cancer	9.12e-05	0.000283	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—bone cancer	9.05e-05	0.000281	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—bone cancer	9.04e-05	0.00028	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—bone cancer	8.82e-05	0.000274	CcSEcCtD
Cyclophosphamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.78e-05	0.00139	CbGpPWpGaD
Cyclophosphamide—Fatigue—Doxorubicin—bone cancer	8.75e-05	0.000271	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—bone cancer	8.72e-05	0.00027	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—bone cancer	8.68e-05	0.000269	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—bone cancer	8.68e-05	0.000269	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—bone cancer	8.67e-05	0.000269	CcSEcCtD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.66e-05	0.00137	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.66e-05	0.00137	CbGpPWpGaD
Cyclophosphamide—Hypersensitivity—Methotrexate—bone cancer	8.64e-05	0.000268	CcSEcCtD
Cyclophosphamide—CYP2A6—Metabolism—NDUFA12—bone cancer	8.63e-05	0.00137	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.41e-05	0.00133	CbGpPWpGaD
Cyclophosphamide—Asthenia—Methotrexate—bone cancer	8.41e-05	0.000261	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—bone cancer	8.37e-05	0.000259	CcSEcCtD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.3e-05	0.00132	CbGpPWpGaD
Cyclophosphamide—Pruritus—Methotrexate—bone cancer	8.29e-05	0.000257	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—bone cancer	8.08e-05	0.000251	CcSEcCtD
Cyclophosphamide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.08e-05	0.00128	CbGpPWpGaD
Cyclophosphamide—Urticaria—Doxorubicin—bone cancer	8.06e-05	0.00025	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—bone cancer	8.02e-05	0.000249	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—bone cancer	8.02e-05	0.000249	CcSEcCtD
Cyclophosphamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.01e-05	0.00127	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	7.97e-05	0.00126	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.9e-05	0.00125	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.88e-05	0.00125	CbGpPWpGaD
Cyclophosphamide—Asthenia—Epirubicin—bone cancer	7.87e-05	0.000244	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—NT5C3A—bone cancer	7.8e-05	0.00124	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.78e-05	0.00123	CbGpPWpGaD
Cyclophosphamide—Pruritus—Epirubicin—bone cancer	7.76e-05	0.000241	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—bone cancer	7.75e-05	0.00024	CcSEcCtD
Cyclophosphamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.51e-05	0.00119	CbGpPWpGaD
Cyclophosphamide—Diarrhoea—Epirubicin—bone cancer	7.51e-05	0.000233	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—bone cancer	7.48e-05	0.000232	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—bone cancer	7.45e-05	0.000231	CcSEcCtD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.41e-05	0.00117	CbGpPWpGaD
Cyclophosphamide—Rash—Methotrexate—bone cancer	7.39e-05	0.000229	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—bone cancer	7.38e-05	0.000229	CcSEcCtD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.37e-05	0.00117	CbGpPWpGaD
Cyclophosphamide—Headache—Methotrexate—bone cancer	7.34e-05	0.000228	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—bone cancer	7.28e-05	0.000226	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—bone cancer	7.25e-05	0.000225	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—bone cancer	7.18e-05	0.000223	CcSEcCtD
Cyclophosphamide—CYP2A6—Metabolism—NT5C3A—bone cancer	7.15e-05	0.00113	CbGpPWpGaD
Cyclophosphamide—Vomiting—Epirubicin—bone cancer	6.98e-05	0.000216	CcSEcCtD
Cyclophosphamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.97e-05	0.0011	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NDUFA12—bone cancer	6.97e-05	0.0011	CbGpPWpGaD
Cyclophosphamide—Nausea—Methotrexate—bone cancer	6.96e-05	0.000216	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—bone cancer	6.95e-05	0.000215	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—bone cancer	6.92e-05	0.000215	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—bone cancer	6.91e-05	0.000214	CcSEcCtD
Cyclophosphamide—CYP2D6—Biological oxidations—GSTP1—bone cancer	6.91e-05	0.00109	CbGpPWpGaD
Cyclophosphamide—Headache—Epirubicin—bone cancer	6.87e-05	0.000213	CcSEcCtD
Cyclophosphamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.85e-05	0.00109	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	6.81e-05	0.00108	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NDUFA12—bone cancer	6.81e-05	0.00108	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.75e-05	0.00107	CbGpPWpGaD
Cyclophosphamide—Dizziness—Doxorubicin—bone cancer	6.71e-05	0.000208	CcSEcCtD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.59e-05	0.00104	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.57e-05	0.00104	CbGpPWpGaD
Cyclophosphamide—Nausea—Epirubicin—bone cancer	6.52e-05	0.000202	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—bone cancer	6.45e-05	0.0002	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—bone cancer	6.4e-05	0.000198	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—bone cancer	6.39e-05	0.000198	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—bone cancer	6.36e-05	0.000197	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—bone cancer	6.03e-05	0.000187	CcSEcCtD
Cyclophosphamide—CYP2C8—Metabolism—NDUFA12—bone cancer	5.9e-05	0.000935	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NT5C3A—bone cancer	5.77e-05	0.000915	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.67e-05	0.000899	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NT5C3A—bone cancer	5.64e-05	0.000894	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NDUFA12—bone cancer	5.26e-05	0.000834	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—ENO2—bone cancer	5.14e-05	0.000815	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NDUFA12—bone cancer	5.14e-05	0.000814	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.89e-05	0.000774	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NT5C3A—bone cancer	4.89e-05	0.000774	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NDUFA12—bone cancer	4.84e-05	0.000767	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NDUFA12—bone cancer	4.8e-05	0.000761	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—DHFR—bone cancer	4.77e-05	0.000756	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.52e-05	0.000716	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—GNA11—bone cancer	4.46e-05	0.000707	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.45e-05	0.000706	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NT5C3A—bone cancer	4.36e-05	0.000691	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NT5C3A—bone cancer	4.26e-05	0.000675	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP3A4—bone cancer	4.04e-05	0.000641	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NT5C3A—bone cancer	4.01e-05	0.000636	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NT5C3A—bone cancer	3.98e-05	0.00063	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.62e-05	0.000574	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.49e-05	0.000553	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—GSTP1—bone cancer	3.46e-05	0.000548	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ENO2—bone cancer	3.42e-05	0.000542	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—DHFR—bone cancer	3.17e-05	0.000503	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NDUFA12—bone cancer	3.17e-05	0.000502	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.15e-05	0.000499	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ENO2—bone cancer	3.13e-05	0.000497	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GNA11—bone cancer	2.96e-05	0.00047	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—DHFR—bone cancer	2.91e-05	0.000461	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GNA11—bone cancer	2.72e-05	0.000431	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP3A4—bone cancer	2.69e-05	0.000426	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NT5C3A—bone cancer	2.62e-05	0.000416	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ENO2—bone cancer	2.53e-05	0.000401	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.48e-05	0.000392	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ENO2—bone cancer	2.47e-05	0.000392	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP3A4—bone cancer	2.46e-05	0.00039	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—DHFR—bone cancer	2.35e-05	0.000372	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTP1—bone cancer	2.3e-05	0.000364	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—DHFR—bone cancer	2.29e-05	0.000363	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GNA11—bone cancer	2.19e-05	0.000347	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GNA11—bone cancer	2.14e-05	0.00034	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ENO2—bone cancer	2.14e-05	0.000339	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTP1—bone cancer	2.11e-05	0.000334	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.08e-05	0.000329	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP3A4—bone cancer	1.99e-05	0.000315	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—DHFR—bone cancer	1.99e-05	0.000315	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP3A4—bone cancer	1.94e-05	0.000308	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ENO2—bone cancer	1.91e-05	0.000303	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ENO2—bone cancer	1.86e-05	0.000296	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GNA11—bone cancer	1.86e-05	0.000294	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTGS2—bone cancer	1.79e-05	0.000284	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—DHFR—bone cancer	1.77e-05	0.000281	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ENO2—bone cancer	1.76e-05	0.000278	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ENO2—bone cancer	1.74e-05	0.000276	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—DHFR—bone cancer	1.73e-05	0.000274	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTP1—bone cancer	1.7e-05	0.000269	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP3A4—bone cancer	1.68e-05	0.000267	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.67e-05	0.000265	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTP1—bone cancer	1.66e-05	0.000263	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GNA11—bone cancer	1.66e-05	0.000263	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—DHFR—bone cancer	1.63e-05	0.000258	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GNA11—bone cancer	1.62e-05	0.000256	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—DHFR—bone cancer	1.62e-05	0.000256	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GNA11—bone cancer	1.52e-05	0.000241	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GNA11—bone cancer	1.51e-05	0.000239	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP3A4—bone cancer	1.5e-05	0.000238	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.49e-05	0.000237	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP3A4—bone cancer	1.47e-05	0.000232	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTP1—bone cancer	1.44e-05	0.000228	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP3A4—bone cancer	1.38e-05	0.000219	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP3A4—bone cancer	1.37e-05	0.000217	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.36e-05	0.000216	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTP1—bone cancer	1.28e-05	0.000204	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTP1—bone cancer	1.25e-05	0.000199	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTGS2—bone cancer	1.19e-05	0.000189	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTP1—bone cancer	1.18e-05	0.000187	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTP1—bone cancer	1.17e-05	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ENO2—bone cancer	1.15e-05	0.000182	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTGS2—bone cancer	1.09e-05	0.000173	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—DHFR—bone cancer	1.07e-05	0.000169	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GNA11—bone cancer	9.96e-06	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTGS2—bone cancer	8.81e-06	0.00014	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTGS2—bone cancer	8.61e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTP1—bone cancer	7.72e-06	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTGS2—bone cancer	7.46e-06	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTGS2—bone cancer	6.65e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTGS2—bone cancer	6.49e-06	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTGS2—bone cancer	6.12e-06	9.7e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTGS2—bone cancer	6.07e-06	9.62e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTGS2—bone cancer	4e-06	6.34e-05	CbGpPWpGaD
